Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 November 2024 | Story Leonie Bolleurs | Photo Stephen Collett
SARIMA - 2024
The Directorate Research Development at the university proudly participates in the SARIMA Visibility Project, aimed at enhancing its global visibility and research excellence.

The University of the Free State (UFS) has been selected to participate in a high-impact initiative managed and coordinated by the Southern African Research and Innovation Management Association (SARIMA). The SARIMA Visibility Project, which focuses on elevating institutional prominence, aims to enhance the university’s global visibility and strengthen its capacity to secure international grants. By participating in this initiative, the UFS is positioning the Directorate for Research and Development (DRD) to benchmark against other leading Tier 1 institutions, adopting best practices in research management and innovation to fuel future growth.

Key outcomes already underway

Since joining the initiative, the university has implemented several key interventions. Most notably, the development and execution of standardised operating procedures have been introduced. These procedures ensure alignment with global standards, creating consistency across various functions within DRD. Such efforts not only improve operational efficiency, but also boost the university’s competitiveness in attracting international research collaborations and securing funding opportunities. Other platforms to promote visibility that the DRD has adopted this year include its newsletter, Research Nexus, webinars, and a presence on social media.

The SARIMA Visibility Project at the UFS is spearheaded by the DRD under the leadership of Dr Glen Taylor. As pioneers of the initiative, the DRD team is working closely with SARIMA to ensure the successful implementation of key strategies aimed at improving the research infrastructure and elevating the university’s global standing. Their leadership has been instrumental in driving efforts to meet the project's ambitious objectives. These objectives include promoting best practices in research and innovation management across the region. They aim to support the research and innovation ecosystem to drive regional social and economic development. Additionally, the project seeks to engage key stakeholders to strengthen collaboration. Another objective is to building capacity among research and innovation management practitioners through training and development initiatives.

The SARIMA project is closely aligned with the UFS’s Vision 130, a strategic roadmap designed to propel the institution into its 130th anniversary in 2034. Vision 130 seeks to elevate the university’s academic and research standing on the global stage. By enhancing international partnerships and refining research management practices, SARIMA is playing an important role in supporting the university in its goal of becoming a globally recognised research institution, in line with Vision 130.

Value added to the research environment

In the few months since its launch, the SARIMA initiative has already added significant value to the UFS Research Office. The introduction of standardised procedures has not only improved consistency across departments, but has also made the office more agile and responsive to the demands of international collaborations. Benchmarking exercises conducted as part of the project have allowed the university to identify key areas for improvement, adopting innovative solutions that further enhance the institution’s research capacity and global visibility.

The SARIMA Visibility Project marks a significant step forward for the university. It is not only a means of raising the institution’s profile, but also a platform for long-term sustainable research excellence. As the UFS continues to benefit from this initiative, it is setting the stage for a future of global recognition and academic achievement that will benefit both the institution and the broader academic community for years to come.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept